Tenax Therapeutics, Inc.
TENX· Nasdaq
TENXTenax Therapeutics, Inc.
Filed Nov 13, 2024 · 10-Q · 44 days after period end · 0001654954-24-014262
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Net Income | -$3.96M | $1.97M | $2.92M | $3.80M |
| EPS Diluted | -$0.19 | — | — | -$0.15 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 13, 2024 · 44 d after period end
